PT - JOURNAL ARTICLE AU - Zekavat, Seyedeh Maryam AU - Sekimitsu, Sayuri AU - Ye, Yixuan AU - Raghu, Vineet AU - Zhao, Hongyu AU - Elze, Tobias AU - Segrè, Ayellet V. AU - Wiggs, Janey L. AU - Natarajan, Pradeep AU - Priore, Lucian Del AU - Zebardast, Nazlee AU - Wang, Jay C. TI - Photoreceptor layer thinning is an early biomarker for age-related macular degeneration development: Epidemiological and genetic evidence from UK Biobank optical coherence tomography data AID - 10.1101/2021.08.18.21262226 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.18.21262226 4099 - http://medrxiv.org/content/early/2021/10/26/2021.08.18.21262226.short 4100 - http://medrxiv.org/content/early/2021/10/26/2021.08.18.21262226.full AB - Introduction Age-related macular degeneration (AMD) is a blinding condition for which there is currently no early-stage clinical biomarker. AMD is characterized by thinning of the outer retina and drusen formation leading to thickening of the Bruch’s membrane and RPE complex, but the timing between these two events, as well as the role of genetic variants in these processes, are unclear. Here, we jointly analyzed genomic, electronic health record, and optical coherence tomography (OCT) data across 44,823 individuals from the UK Biobank to characterize the epidemiological and genetic associations between retinal layer thicknesses and AMD.Methods The Topcon Advanced Boundary Segmentation algorithm was used for automated retinal layer segmentation. We associated 9 retinal layer thicknesses with prevalent AMD (present at enrollment) in a logistic regression model, and with incident AMD (diagnosed after enrollment) in a Cox proportional hazards model. Next, we tested the association of AMD-associated genetic alleles, individually and as a polygenic risk score (PRS), with retinal layer thicknesses. All analyses were adjusted for age, age2, sex, smoking status, and principal components of ancestry.Results Photoreceptor segment (PS) thinning was observed throughout the lifespan of individuals analyzed and accelerated at age 45, while retinal pigment epithelium and Bruch’s membrane complex (RPE+BM) thickening started after age 57. Each standard deviation (SD) of PS thinning and RPE+BM thickening were associated with prevalent AMD (PS: OR 1.37, 95% CI 1.25-1.49, P=2.5×10−12; RPE+BM: OR=1.34, 95% CI 1.27-1.41, P=8.4×10−28) and incident AMD (PS: HR 1.35, 95% CI 1.23-1.47, P=3.7×10−11; RPE+BM: HR 1.14, 95% CI 1.06-1.22, P=0.00024). An AMD polygenic risk score (PRS) was associated with PS thinning (Beta -0.21 SD per 2-fold genetically increased risk of AMD, 95% CI -0.23 to -0.19, P=2.8×10−74), and its association with RPE+BM was U-shaped (thinning with AMD PRS<92nd percentile and thickening with AMD PRS>92nd percentile suggestive of drusen formation). The loci with strongest support were AMD risk-raising variants CFH:rs570618-T, CFH:10922109-C, and ARMS2/HTRA1:rs3750846-C on PS thinning, and SYN3/TIMP3:rs5754227-T on RPE+BM thickening.Conclusions Epidemiologically, PS thinning precedes RPE+BM thickening by decades, and is the retinal layer most strongly predictive of future AMD risk. Genetically, AMD risk variants are associated with decreased PS thickness. Overall, these findings support PS thinning as an early-stage clinical biomarker for future AMD development.Competing Interest StatementP.N. reports grants from Amgen, Boston Scientific, Apple, and AstraZeneca., personal fees from Novartis, Blackstone Life Sciences, Apple, AstraZeneca, Genentech, and Foresite Labs, and spousal employment at Vertex all outside the submitted work. . J.L.W. has received grant support from Aerpio and served as a consultant for Allergan, Avellino, Editas, Maze, and Regenxbio outside of the present work. No conflicting relationship exists for other authors.Funding StatementS.M.Z. is supported by the NIH National Heart, Lung, and Blood Institute (1F30HL149180-01) and the NIH Medical Scientist Training Program Training Grant (T32GM136651). P.N. is supported by a Hassenfeld Scholar Award from the Massachusetts General Hospital, and grants from the National Heart, Lung, and Blood Institute (R01HL1427, R01HL148565, and R01HL148050). J.L.W. is supported in part by NEI (R01EY020928, R01EY022305, R01EY031820, R01EY032559). N.Z. is supported by the National Eye Institute (NEI) 1K23EY032634.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of the data was approved by the Massachusetts General Hospital Institutional Review Board (protocol 2021P002040) and facilitated through UK Biobank Applications 7089 and 50211.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUKB individual-level data are available for request by application (https://www.ukbiobank.ac.uk).